Many plans have different rules, and what one person's plan covers might be totally different from another's, even if they both have Blue Cross Blue Shield
Selecting the correct subcutaneous vs intramuscular peptide injection route for each compound should follow the primary literature whenever available: Key insight: BPC-157 is unique in that published research shows it produces systemic effects regardless of injection site
In this video, @lisa_jewell_md_plasticsurgery explains that treatment is highly individualized
Appetite suppression timing varies, and some people require higher doses or longer treatment duration
With respect to GLP-1RAs, liraglutide and semaglutide have demonstrated a reduction in the risk of major adverse cardiovascular events (MACE) [16, 17], and, while yet not published, early reports for dulaglutide indicate CV benefits in patients with a wide range of CV risk [18]